CYTENA’s B.SIGHTTM will reduce timelines and cut costs on single-cell microbiology research
FREIBURG, Germany, August 08, 2022 / B3C newswire / -- CYTENA, a BICO group company (Nasdaq Stockholm: BICO), a leading provider of high-precision instruments for handling biological cells, has launched a new instrument to streamline single-cell isolation in microbiology research. The next generation B.SIGHT is taking the company’s automated single-cell isolation capabilities to the next level with special emphasis on handling bacteria, yeast and other microorganisms.
“The new B.SIGHT brings isolation of bacteria & yeast to the next level” said Dr. Julian Riba, CEO of CYTENA. “This second generation single-cell dispenser is really the outcome of a great collaboration between our team and our customers.”
For years, microbiologists have been interested in fully automating single-cell isolation from complex sample suspension in order to characterize unknown species. The new B.SIGHT has been designed to tackle this challenge efficiently and reliably. “The new instrument provides more automation, faster processing speeds, higher resolution and precise dispensing,” said Dr. Hussein Hamzeh, the B.SIGHT’s Product Manager. Dr. Hamzeh also explained that, in addition to optimizing workflows, the B.SIGHT follows CYTENA’s philosophy on customer-conscious product design. “Researchers using the B.SIGHT not only will be able to accelerate microorganism isolation workflows but also significantly reduce plastic waste.”
CYTENA believes the new B.SIGHT will accelerate and automate microbial cloning workflows in Pharma and Biotech companies. It will also revolutionize the microbiome field by enabling scientists to streamline their microbiome work and accelerate their path towards transformative medicine. “We’re confident we can grow together with the customers who will introduce the B.SIGHT to their lab.” said Dr. Riba.
About CYTENA
CYTENA is a leading provider of high-precision instruments for isolating, dispensing, imaging, analyzing and handling biological cells. The Company continues to build on the success of the single-cell dispensing technology it patented as a spin-off from the University of Freiburg, Germany in 2014. Today, as part of BICO, the world’s leading bioconvergence company, CYTENA’s award-winning devices are still manufactured in Germany and used at prestigious academic and pharmaceutical labs around the world to automate workflows in numerous application areas, including stable cell line development, single-cell omics, high-throughput screening and drug discovery.
CYTENA’s breakthrough innovations for the lab combine advanced automation, state-of-the-art software engineering and the latest insights in cell biology to maximize efficiencies in the life sciences and create the future of health.
Contact
Fabian Stumpf
CMO, CYTENA
Phone (Germany): +49 761 2163 2000
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Cloning, Molecular; Clone Cells; Cell Separation; Saccharomyces cerevisiae; Bacteria; Biomedical Research; Microbiology; Laboratories; Technology; Medical Waste Disposal; Plastics; Equipment and Supplies; Biotechnology; Germany
Published by B3C newswire